zbh beat our/consensu expect sale sever segment beat led
knees/hip ep higher sale gm sale guidanc ahead
us/street organ stronger underli trend slight benefit
extra sell day ep guidanc bracket consensu introduc
new restructur initi target oper margin least
om guidanc fda recent complet re-inspect north
campu facil manag see remain observ address rosa
knee impact increas rosa spine hip also target overal
manag reiterated/highlight sever driver continu improv growth
salesforc confid suppli stabil pivot increas manufactur effici
increas new product flow
reconstruct market firm report hip/kne days-adjust growth
jnj/syk/zbh market acceler versu
despit tougher comp growth three compani
knee/hip price versu
line jnj/syk note stabl improv orthoped price messag
rosa updat rosa placement contribut littl half overal knee
growth assum sale custom pipelin continu
grow feedback remain strong rosa spine still track expect launch
management note rosa hip also expect launch believ
spine/hip launch underappreci opportun
guidanc inclus restructur charg
solid guid view fda recent complet re-inspect warsaw
north campu management indic eight observ management highli
confid satisfi remain observ note signific progress
site suppli remain non-factor shift offens
restructur initi multi-year restructur plan reduc cost
reinvest higher-growth opportun management target pre-tax save reach
restructur charg estim
slightli half near term management note cost-sav opportun
identifi throughout organ along reorgan busi unit
footprint consolid one mention long-term initi
estim sale rise report primarili
higher knees/hip ep remain sale estim rise
ep use cash
repres upsid estim higher estim pt rise
year price histori
manufactur
distribut orthoped dental
trauma product relat surgic
analyst certif import disclosur see disclosur
underli sale growth improv full year sale growth
free cash flow use pay debt guidanc
oper margin leverag slightli improv acceler
announc restructur program
quicker share recaptur improv suppli
faster acceler busi outsid large-joint ortho
use growth enhanc tuck-in
price-to-earnings share trade discount
large-cap peer mileston look forward
shift focu improv suppli cost reduct initi
continu build-out special salesforc new
product launch led robot knee spine system knee
on-going spine persona cementless full launch
on-going launch rosa knee persona cementless knee
launch rosa spine hip
benefit salesforc build-out
slower expect hip/kne market growth
greater expect impact competitor rollout
price target driven blend discount cash flow compar pe analysi dcf use weight
averag cost capit wacc termin growth rate estim ebitda target impli
price-to-earnings multipl ep
risk price target includ wors expect price pressur key market declin procedur macro headwind
greater expect impact competitor rollout
includ expect one-tim gross margin benefit revers previou med-tech tax accrual bp estim posit impact
stock price compani mention report
